secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2024-12-05T23:59:59+00:00
Accession:  0001193125-24-271116
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology reports 74.5% CR rate in Phase 3 BOND-003; median DOR >27 months
----------------------------------------------------------------------------

- 74.5% (82/110) achieved complete response at any time (95% CI 65.4-82.4%).
- Median duration of response not reached but exceeds 27 months; 63.5% probability of response at 12 months.
- No Grade 3+ treatment-related adverse events or deaths; 97.3% completed all treatments.
- Progression-free survival at 12 months: 97.3%; no progression to muscle-invasive cancer.
- Cystectomy-free survival at 12 months: 90.0%; 50% of reinduced patients converted to CR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000119312524271116/0001193125-24-271116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000119312524271116/d809707d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-271116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer